PS-1145

• Description:

  PS-1145 is an IκB kinase (IKK) inhibitor with an IC50 of 88 nM.

• UNSPSC:

  12352005

• Hazard Statement:

  H302

• Target:

  Apoptosis; IKK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; NF-κB

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/PS-1145.html

• Concentration:

  10mM

• Purity:

  99.88

• Solubility:

  DMSO : 20.83 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=CN=C1)NC2=CC(Cl)=CC3=C2NC4=C3C=CN=C4

• Molecular Formula:

  C17H11ClN4O

• Molecular Weight:

  322.75

• Precautions:

  H302

• References & Citations:

  [1]Hideshima T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10;277 (19) :16639-47.|[2]Vodanovic-Jankovic S, et al. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood. 2006 Jan 15;107 (2) :827-34.|[3]Oh-I S, et al. Central administration of interleukin-4 exacerbates hypothalamic inflammation and weight gain during high-fat feeding. Am J Physiol Endocrinol Metab. 2010 Jul;299 (1) :E47-53.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IKK

• CAS Number:

  [431898-65-6]